



**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123  
 Regd. Office: Alembic Road, Vadodara 390 003  
 Tel: +91 265 2280550  
 Email: apl.investors@alembic.co.in  
 Website: www.alembicpharmaceuticals.com

**Extract of Statement of Consolidated Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2021.**

(₹ in Crs. except per share data)

Particulars	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
	Unaudited	Unaudited	Audited
Total Income from Operations	1,326.03	1,341.32	5,393.13
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	182.55	359.50	1,368.08
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	182.55	359.50	1,368.08
Net Profit for the period after tax (after Exceptional and/ or Extraordinary items)	164.52	301.46	1,178.11
Total Comprehensive Income for the period	155.61	287.46	1,142.81
Equity Share Capital	39.31	37.70	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	5,088.30
Earning Per Share (Face Value of Rs. 2/- each) Basic & Diluted	8.37	15.99	60.81
Research and Development Expenses	167.21	142.61	670.00

**Notes:**

1. Standalone details	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
	Unaudited	Unaudited	Audited
Income from Operations	1,269.69	1,258.43	5,051.44
Profit Before Tax	233.19	381.57	1,416.60
Profit After Tax	192.69	318.64	1,175.39
Research and Development Expenses	154.43	128.46	631.01

2. The above is an extract of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited  
 Sd/-

Place: Vadodara  
 Date: 26<sup>th</sup> July, 2021

Pranav Amin  
 Managing Director